NASDAQ:UNCY - Unicycive Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $13.50
  • Forecasted Upside: 392.70 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$2.74
▲ +0.13 (4.98%)

This chart shows the closing price for UNCY by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Unicycive Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for UNCY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for UNCY

Analyst Price Target is $13.50
▲ +392.70% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Unicycive Therapeutics in the last 3 months. The average price target is $13.50, with a high forecast of $13.50 and a low forecast of $13.50. The average price target represents a 392.70% upside from the last price of $2.74.

This chart shows the closing price for UNCY for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 contributing investment analysts is to buy stock in Unicycive Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/1/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/30/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/28/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/27/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/25/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/24/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/17/2021BenchmarkInitiated CoverageBuyHigh
8/9/2021Roth CapitalInitiated CoverageBuy$13.50High
(Data available from 9/23/2016 forward)

News Sentiment Rating

0.33 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/27/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/26/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/25/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/25/2021
  • 0 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
8/24/2021
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
9/23/2021

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Unicycive Therapeutics logo
Unicycive Therapeutics Inc. is a clinical stage biotechnology company. It involved in developing therapies for patients with kidney disease. The company's lead drug consist Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia. Unicycive Therapeutics Inc. is based in LOS ALTOS, Calif.
Read More

Today's Range

Now: $2.74
Low: $2.63
High: $2.86

50 Day Range

MA: $2.79
Low: $2.47
High: $3.74

52 Week Range

Now: $2.74
Low: $2.39
High: $8.73

Volume

3,543 shs

Average Volume

818,132 shs

Market Capitalization

$39.75 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Unicycive Therapeutics?

The following Wall Street research analysts have issued reports on Unicycive Therapeutics in the last year: Benchmark Co., and Roth Capital.
View the latest analyst ratings for UNCY.

What is the current price target for Unicycive Therapeutics?

1 Wall Street analysts have set twelve-month price targets for Unicycive Therapeutics in the last year. Their average twelve-month price target is $13.50, suggesting a possible upside of 392.7%. Roth Capital has the highest price target set, predicting UNCY will reach $13.50 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $13.50 for Unicycive Therapeutics in the next year.
View the latest price targets for UNCY.

What is the current consensus analyst rating for Unicycive Therapeutics?

Unicycive Therapeutics currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe UNCY will outperform the market and that investors should add to their positions of Unicycive Therapeutics.
View the latest ratings for UNCY.

How do I contact Unicycive Therapeutics' investor relations team?

Unicycive Therapeutics' physical mailing address is 5150 EL CAMINO REAL SUITE A-32, LOS ALTOS CA, 94022. The company's listed phone number is 650-351-4495 and its investor relations email address is [email protected] The official website for Unicycive Therapeutics is www.unicycive.com.